143165-32-6

Basic information

• Product Name: 3-(1,4-DIOXASPIRO[4.5]DEC-7-EN-8-YL)-1H-INDOLE
• Synonyms: 3-(1,4-DIOXASPIRO[4.5]DEC-7-EN-8-YL)-1H-INDOLE;4-(1H-Indol-3-yl)cyclohex-3-en-1-one ethylene ketal, 8-(1H-Indol-3-yl)-1,4-dioxaspiro[4.5]dec-7-ene
• CAS NO: 143165-32-6
• Molecular Formula: C₁₆H₁₇NO₂
• Molecular Weight: 255.31
• Mol File: 143165-32-6.mol
• Article Data: 11

Chemical Properties

• Melting Point: 194-196
• Boiling Point: 458.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.25±0.1 g/cm3(Predicted)
• PKA: 17.09±0.30(Predicted)
• CAS DataBase Reference: 3-(1,4-DIOXASPIRO[4.5]DEC-7-EN-8-YL)-1H-INDOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1,4-DIOXASPIRO[4.5]DEC-7-EN-8-YL)-1H-INDOLE(143165-32-6)
• EPA Substance Registry System: 3-(1,4-DIOXASPIRO[4.5]DEC-7-EN-8-YL)-1H-INDOLE(143165-32-6)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 143165-32-6(Hazardous Substances Data)

Upstream product

• 120-72-9 indole 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 123-75-1 pyrrolidine 

Downstream Products

• 1352485-19-8 R,S-2-[4-(1H-indol-3-yl)-trans-cyclohexylamino]-2-[1-(trans-3,5-difluorocinnamoyl)piperidin-4-yl]-acetamide 
• 1352428-65-9 C₃₀H₃₄F₂N₄O₂ 
• 1352428-64-8 C₃₀H₃₄F₂N₄O₂ 
• 1352428-63-7 C₃₂H₄₁N₅O₂ 
• 1352428-62-6 C₃₁H₃₅F₃N₄O₃ 
• 1352428-61-5 C₃₁H₃₅F₃N₄O₂ 
• 1352428-60-4 C₃₁H₃₈N₄O₄S 
• 1352428-59-1 C₃₀H₃₅ClN₄O₂ 
• 1352428-58-0 C₃₀H₃₅FN₄O₂ 
• 1352428-57-9 C₃₀H₃₅FN₄O₂ 
• 1352428-56-8 C₃₀H₃₅FN₄O₂ 
• 1352428-54-6 C₂₈H₃₅N₅O₂ 
• 1352428-53-5 C₂₈H₃₄N₄O₂ 
• 1352428-52-4 C₂₉H₃₆N₄O₂ 

Relevant articles and documents

4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, X, Y, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

6-BENZYL-2,3,4,7-TETRAHYDRO-INDOLO[2,3-C]QUINOLINE COMPOUNDS

The present invention pertains to 6-benzyl-2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds of formula (I), as well as the resulting pharmaceutical compositions, and their use in the treatment or prophylaxis of diseases alleviated by inhibition of type 5 phosphodiesterases. Furthermore, the present invention pertains to the methods of manufacturing these 6-benzyl-2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds.

ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION

Compounds are provided which are useful for the treatment of serotonin-affected neurological disorders which comprise (I) wherein: Ra, R1, R2 and R3 are each, independently, hydrogen, or a substituent selected from halogen, CF3, alkyl, alkoxy, MeSO2, amino or aminocarbonyl (each optionally substituted by one or two groups selected from alkyl and benzyl) carboxy, or alkoxycarbonyl; or two adjacent of Ra and R1-4 together can form a 5-7 membered carbocyclic or heterocyclic ring which is optionally substituted by a substituent defined above; R4 is hydrogen, halogen, or alkyl; R5 is hydrogen, alkyl, arylalkyl, or aryl; R6 is hydrogen, halogen, CF3, CN, carbamide, alkoxy or benzyloxy; X1, X2 and X3 are each carbon or one of X1, X2 or X3 may be nitrogen; Y is CH or nitrogen; and Z is carbon or nitrogen; or pharmaceutically acceptable salts thereof.